Source: Virtual Congress 2020 – Pulmonary vascular diseases
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
J. Pepke-Zaba (Cambridge, United Kingdom). PROs: which instruments are available in pulmonary hypertension?. Virtual Congress 2020 – Pulmonary vascular diseases

Member's Comments

No comment yet.

Related content which might interest you: Quality of online information on pulmonary arterial hypertension. Source: Virtual Congress 2020 – Epidemiology and treatment of pulmonary arterial hypertension Year: 2020 EmPHasis-10 is associated with clinical outcome measures in pulmonary hypertension Source: Annual Congress 2013 –Pulmonary circulation: clinical diagnosis, imaging, biomarkers and treatment Year: 2013 Learning from registries in pulmonary arterial hypertension: pitfalls and recommendations Source: Eur Respir Rev, 28 (154) 190050; 10.1183/16000617.0050-2019 Year: 2019 CAMPHOR score: patient-reported outcomes are improved by pulmonary endarterectomy in chronic thromboembolic pulmonary hypertension Source: Eur Respir J, 56 (4) 1902096; 10.1183/13993003.02096-2019 Year: 2020 Cambridge pulmonary hypertension outcomes review (CAMPHOR) utility assessment in pulmonary hypertension (PH) patients Source: Annual Congress 2007 - Pulmonary hypertension in the clinic Year: 2007 Responsiveness of cambridge pulmonary hypertension outcome review (CAMPHOR) scores and utility in pulmonary hypertension (PH) patients Source: Eur Respir J 2007; 30: Suppl. 51, 343s Year: 2007 The CAMbridge pulmonary hypertension outcome review (CAMPHOR): development and validation Source: Eur Respir J 2004; 24: Suppl. 48, 111s Year: 2004 Pulmonary hypertension therapy and COPD: still many questions to be answered Source: Eur Respir J 2009; 33: 449 Year: 2009 Pulmonary rehabilitation in patients with group 3 pulmonary hypertension: evaluation of clinical outcomes, adherence and safety. Source: International Congress 2019 – The future of pulmonary rehabilitation discussed today Year: 2019 Pulmonary arterial hypertension patients underrepresented in clinical trials – Are they different? Source: International Congress 2016 – Pulmonary hypertension: the clinic II Year: 2016 TOPP: the first international registry in pediatric pulmonary hypertension Source: Annual Congress 2008 - Pulmonary hypertension I Year: 2008 EmPHasis-10 as a measure of health-related quality of life in pulmonary arterial hypertension: data from PHAR Source: Eur Respir J, 57 (2) 2000414; 10.1183/13993003.00414-2020 Year: 2021 Combination therapy for pulmonary arterial hypertension: still more questions than answers Source: Eur Respir J 2004; 24: 339-340 Year: 2004 Comparison of cardiac and pulmonary-specific quality-of-life measures in pulmonary arterial hypertension Source: Eur Respir J 2011; 38: 608-616 Year: 2011 End-points and clinical trial design in pulmonary arterial hypertension: have we made progress? Source: Eur Respir J 2009; 34: 231-242 Year: 2009 Clinical trials in pulmonary arterial hypertension: what do they tell us Source: ERS Course 2017 - Pulmonary Hypertension and Pulmonary Vascular Disease Year: 2017 Clinical trials in pulmonary arterial hypertension: what do they tell us Source: ERS Skills course - Pulmonary hypertension and pulmonary vascular disease Year: 2018 Clinical trials in pulmonary arterial hypertension: what they tell us Source: ERS Course 2020 - Pulmonary hypertension and pulmonary vascular disease Year: 2020 Treatment of pulmonary hypertension due to COPD: can we really hope in better? Source: Eur Respir J 2005; 26: Suppl. 49, 562s Year: 2005 A pilot study of digital feedback to guide therapeutic decisions in pulmonary hypertension Source: International Congress 2016 – Pulmonary hypertension: the clinic II Year: 2016